




# Targeted BEACOPP: Study Flow



# Recruitment as of March, 2014 (104)



# Study Flow



2. termination before start of treatment (BRECAPP group)

3. Treatment relevant revision of initial staging, violation of inclusion criterium (BRECAPP group)

4. termination after 2 cycles due to toxicity of treatment. Restaging result: PET-2 negative PR. This patient reached a complete remission after additional treatment with 4 cycles of ABVD (BRECAPP group)

# Patient Characteristics I

	Targeted BEACOPP N = 104 <sup>1</sup>	HD 15 6 x BEACOPP N = 711
<b>Age</b> median (range)	29 (18-60)	34 (18-60)
<b>Sex</b>		
Female	41 40%	280 (39.4)
Male	62 60%	431 (60.6%)
<b>B- Symptoms</b>	69 68%	453 (63.7%)
<b>Ann Arbor stage</b>		
IIB	17 (17%)	104 (14.6%)
IIIA	23 (23%)	178 (25.0%)
IIIB	20 (20%)	179 (25.2%)
IVA	10 (10%)	78 (11.0%)
IVB	32 (31%)	170 (23.9%)

<sup>1</sup> Data for the last recruited patient have not yet been entered into the data base.